As the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health officials as an important way to reduce the risk of severe illness or death.
Yet the drugs have remained underused, studies have found. In Boston, a group of researchers wanted to know why — and what could be done about it.
Their new findings, published Thursday by the U.S. Centers for Disease Control and Prevention, suggest that some vulnerable patients were not offered the prescription medicines at all, and that doctors need more education to make sure the drugs get to patients who could benefit.
Researchers from the VA Boston Cooperative Studies Program delved into records from the Veterans Health Administration to look more closely at what happened to high-risk patients who never got Paxlovid, remdesivir or molnupiravir. They focused on 110 patients who received organ transplants or had other medical conditions such as chronic lymphocytic leukemia that were likely to leave them immunocompromised and thus at greater risk from COVID-19 despite being vaccinated.
Their analysis in the CDC’s Morbidity and Mortality Weekly Report found that 20 percent of those patients turned down the drugs when they were offered. But the remaining 80 percent of patients were never offered such treatment in the first place.
In some cases, medical providers decided not to give patients the COVID-19 drugs because they were worried about how they could interact with other medications patients were already taking, including cholesterol-lowering statins and a drug used to reduce the risk that a transplanted organ would be rejected. In other cases, doctors demurred because their patients had experienced COVID-19 symptoms for more than five days beforehand, beyond the recommended window for getting Paxlovid.
Despite public alarm about “Paxlovid rebound,” in which symptoms recur after treatment, none of the medical records noted it as a reason not to give the drug, the study found. But in almost half of the cases in which people weren’t offered the medication, no reason was given by medical providers other than patients having mild symptoms, the researchers found.
But people with mild symptoms early in their illness are “exactly the target group for getting the treatment,” said Dr. Paul Monach, who heads the rheumatology section at the Veterans Affairs Boston Healthcare System and was the study’s lead author.
The drugs are recommended for people with mild to moderate COVID-19 who are at high risk of severe illness due to their age or medical conditions — the same kind of patients that the Boston researchers were scrutinizing. The CDC urges doctors to treat high-risk patients within five days rather than waiting for their symptoms to worsen.
“Every case starts off mild,” and it’s unpredictable whether they will become more severe, said Dr. Davey Smith, an infectious disease specialist at the University of California San Diego who was not involved in the study. “It might not be until the fifth or sixth day that you get into trouble — and by that time, it’s too late to take these medications.”
Smith said he was especially alarmed that people whose immune systems were weakened were not getting the antiviral drugs. “Those are the people who are still coming into our hospital,” he said. “And those are the ones who are dying. … It breaks my heart every time I see them in the hospital and they just didn’t get the medication.”
The Boston researchers said their findings suggest that physicians need more education about when to consider using the drugs. Patients, in turn, could be encouraged to reach out to medical providers sooner after they start showing symptoms.
Monach added that some Veterans Health patients who weren’t offered the drugs had gone home before their coronavirus test results had been returned. Clinical staff such as nurses had phoned them to follow up but did not appear to have mentioned the possibility of antiviral medication, based on the records reviewed by the researchers.
“That doesn’t mean that people weren’t doing their jobs,” Monach said, “but I don’t think those people had been informed, as part of their normal jobs, what the indication would be for giving Paxlovid.”
Concerns about Paxlovid and other COVID-19 medications not reaching patients who could benefit have persisted since soon after the drugs became available. Just months after Paxlovid received emergency use authorization from the Food and Drug Administration, a national survey from the COVID States Project found that among people infected with the coronavirus between May and early July 2022, only 11 percent reported having taken antivirals.
